Huadong Medicine announced on November 27 that its globally innovative drug Somituximab monovalent antibody injection (Erahel/ELAHERE) has been approved by the National Medical Products Administration (NMPA) for the indication of platinum-resistant ovarian cancer (PROC) with folate receptor alpha positive who have received previous 1-3 lines of systemic therapy. Somituximab monovalent antibody injection is the first and currently the only targeted FRα antibody-drug conjugate (ADC) approved for PROC treatment in China, the United States, and the European Union. According to Huadong Medicine, after the approval and launch in the United States, the sales volume of Somituximab monovalent antibody injection has been continuously increasing. AbbVie's financial report shows that in the third quarter of 2024, ELAHERE recorded sales of USD 0.139 billion, a 32.23% increase compared to the same period last year, with sales of USD 0.331 billion in the first three quarters, a 56.13% year-on-year growth.